苯甲酸钠辅助氯氮平治疗难治性精神分裂症:随机双盲安慰剂对照试验
两种剂量苯甲酸钠在阴性症状量表改善上均优于安慰剂,2 g/日剂量还在PANSS总分、阳性分及生活质量量表上优于安慰剂,且耐受性良好。
要点
- 苯甲酸钠辅助氯氮平可改善难治性精神分裂症阴性症状。
- 2 g/日苯甲酸钠还改善PANSS总分、阳性分及生活质量。
- 苯甲酸钠耐受性良好,未出现明显副作用。
核心结论
- 苯甲酸钠辅助治疗改善了氯氮平抵抗性精神分裂症患者的症状。
- 需进一步研究明确苯甲酸钠的最佳剂量、治疗时长及机制。
研究设计与样本
- 患者随机分为1 g/日苯甲酸钠、2 g/日苯甲酸钠或安慰剂三组,辅助治疗6周。
- 主要结局指标为PANSS总分、阴性症状量表、生活质量量表和总体功能评估。
- 同时测量副作用和认知功能。
主要发现
- 两种剂量苯甲酸钠在阴性症状量表改善上均优于安慰剂。
- 2 g/日苯甲酸钠在PANSS总分、PANSS阳性分和生活质量量表上改善优于安慰剂。
- 苯甲酸钠耐受性良好,无明显副作用。
- 过氧化氢酶变化在三组间不同,且在苯甲酸钠组与PANSS总分和阳性分改善相关。
临床怎么用
- 对于氯氮平治疗效果不佳的精神分裂症患者,可考虑联用苯甲酸钠辅助治疗。
- 2 g/日剂量可能带来更广泛的症状和生活质量改善。
局限性
- 治疗时长仅6周,长期疗效和安全性未知。
- 最佳剂量和治疗时长尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine. METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that had been stabilized with clozapine were allocated into three groups for 6 weeks' add-on treatment of 1 g/day sodium benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and Global Assessment of Functioning. Side effects and cognitive functions were also measured. RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group. CONCLUSIONS: Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant schizophrenia. Further studies are warranted to elucidate the optimal dose and treatment duration as well as the mechanisms of sodium benzoate for clozapine-resistant schizophrenia.
引用
- Lin CH, Lin CH, Chang YC, et al. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biol Psychiatry. 2017. PMID: 29397899. doi:10.1016/j.biopsych.2017.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。